Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

被引：1
|
作者：
Mienko, Fiona [1 ]
Halmos, Balazs [1 ]
Cheng, Haiying [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 12期
关键词：
PERFORMANCE STATUS; NIVOLUMAB; DOCETAXEL; EFFICACY;
D O I：
10.21037/atm.2020.02.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [42] PD-L1 status in patients of the Moscow region with non-small cell lung cancer
    Byakhova, M.
    Zavalishina, L.
    Andreeva, Y.
    Tsimafeyeu, I.
    Savelov, N.
    Tjulandin, S.
    Frank, G.
    VIRCHOWS ARCHIV, 2020, 477 : S364 - S364
  • [43] PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
    Sorensen, Steffen Filskov
    Zhou, Wei
    Dolled-Filhart, Marisa
    Georgsen, Jeanette Baehr
    Wang, Zhen
    Emancipator, Kenneth
    Wu, Dianna
    Busch-Sorensen, Michael
    Meldgaard, Peter
    Hager, Henrik
    TRANSLATIONAL ONCOLOGY, 2016, 9 (01): : 64 - 69
  • [44] Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression
    Ishizuka, Shiho
    Sakata, Shinya
    Yoshida, Chieko
    Takaki, Akira
    Saeki, Sho
    Nakamura, Kazuyoshi
    Fujii, Kazuhiko
    RESPIRATORY INVESTIGATION, 2018, 56 (04) : 361 - 364
  • [45] Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
    Zhao, Yanjie
    Shi, Feng
    Zhou, Quan
    Li, Yuchen
    Wu, Jiangping
    Wang, Ruibin
    Song, Qingkun
    MEDICINE, 2020, 99 (45) : E23172
  • [46] Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
    Rousseau, Guillaume
    Dantoing, Edouard
    Leturgie, Benedicte
    Tillon-Strozyk, Julie
    Delberghe, Nicolas
    Gregoire, Antoine
    Bota, Suzanna
    Corre, Romain
    Thiberville, Luc
    Guisier, Florian
    CLINICAL LUNG CANCER, 2024, 25 (07) : e323 - e329
  • [47] Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Xueping
    Guo, Zhixing
    Wu, Xingping
    Chen, Da
    Wang, Fang
    Yang, Lewei
    Luo, Min
    Wu, Shaocong
    Yang, Chuan
    Huang, Lamei
    Fu, Liwu
    IMMUNOTARGETS AND THERAPY, 2023, 12 : 1 - 16
  • [48] The role of pembrolizumab in the treatment of advanced non-small cell lung cancer
    Santabarbara, Giuseppe
    Maione, Paolo
    Rossi, Antonio
    Palazzolo, Giovanni
    Gridelli, Cesare
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [49] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [50] Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
    Ali, Wael Abdullah Sultan
    Hui, Pan
    Ma, Yuxiang
    Wu, Yuehan
    Zhang, Yang
    Chen, Yukun
    Hong, Shaodong
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (22)
12345